A phase 1b, open label, multicenter study of the safety and efficacy of MIW815(ADU-S100) administered by intratumoral injection with PDR001 to patients with advanced/metastatic solid tumors or lymphomas

ovartis K K0 sites9 target enrollmentStarted: December 5, 2017Last updated: October 17, 2023

Conditions

Trial Snapshot

Phase: Phase 1
Status: Completed
Sponsor
Enrollment: 9

Study Overview Eligibility Criteria Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Interventional

Eligibility Criteria

Ages: >= 18age old to ot applicable (—)
Sex: All

Inclusion Criteria

•Written informed consent must be obtained prior to any procedures that are not part of standard of care. For Japan only, written consent is necessary both from the patient and his/her legal representative if he/she is under the age of 20 years.
•Male or female over 18 years.
•Patients must have measurable disease as determined by RECIST v1.1 (for solid tumors) or Cheson 2014 criteria (for lymphomas).
•Patients must have at least two sites of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institutions guidelines. /
•Patient must be willing to undergo new tumor biopsies at screening and during therapy on the study according to the treating institutions own guidelines and requirements for such procedure. Exceptions may be considered after documented discussions with Novartis.
•Dose escalation/dose confirmation part of study: Patients with advanced/metastatic solid tumors or lymphomas, who have progressed despite standard therapy or are intolerant to standard therapy, for whom no standard therapy exists or for whom standard therapy is notreasonably effective.
•Dose expansion part of study: Melanoma patients with accessible cutaneous or
•subcutaneous lesions, who have relapsed or progressed after responding to a PD-1 inhibitor or who are refractory to PD-1 inhibitors. Dose expansion will also include patients with accessible cutaneous or subcutaneous lesions with HNSCC or patients with other accessible cutaneous or subcutaneous solid tumors and lymphomas, who have progressed despite standard therapy or are intolerant of standard therapy, for whom no standard therapy exists or for whom standard therapy is not reasonably effective. In addition, patients with injectable visceral lesions who have MSS CRC or other solid tumors with accessible visceral lesions, who have progressed despite standard therapy or are intolerant of standard therapy, for whom no standard therapy exists or for whom standard therapy is not reasonably effective.
•Eastern Cooperative Oncology Group (ECOG) Performance Status under 1.

Exclusion Criteria

•Patients who require immediate local palliative measures such as radiotherapy
•(XRT) or surgery.
•History of severe hypersensitivity reactions to any ingredient of study drug(s)
•and other monoclonal antibodies and/or their excipients
•Active, known or suspected autoimmune disease or a documented history of
•autoimmune disease
•History of or current drug-induced interstitial lung disease or pneumonitis over grade2.
•Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related
•Patients who required discontinuation of study treatment due to treatmentrelated
•toxicities with prior therapy directed against the same target as the drug(s)
•under study in this protocol.

Investigators

Sponsor

ovartis K K

Similar Trials

Completed

Not Applicable

A Phase Ib, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection with PDR001 to patients with advanced/metastatic solid tumors or lymphomas

NL-OMON48864ovartis12

Active, not recruiting

Phase 1

An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)

EUCTR2021-001530-19-HUKartos Therapeutics, Inc.56

Active, not recruiting

Phase 1

An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)MedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-001530-19-ESKartos Therapeutics, Inc.56

Active, not recruiting

Phase 1

EUCTR2021-001530-19-DEKartos Therapeutics, Inc.56

Active, not recruiting

Not Applicable

A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Ageno medical, conditionhealthy, at risk volunteers will be recruited for a clinical trial to receive three vaccinations against meningococcal strain B and one vaccination against meningococcal strains A,C, W and Y.

EUCTR2007-001563-29-DEovartis Vaccines and Diagnostics S.r.l.250